Preemptive short courses of direct-acting antivirals prevented clinically significant donor-transmitted hepatitis C.
The opioid epidemic has produced a growing number of potentially transplantable organs from donors who had hepatitis C virus (HCV) infection. At the same time, the use of direct-acting antivirals (DAAs) has decreased the pool of HCV-infected recipients. To avoid waste of these organs, the liver and kidney transplant community offered HCV-infected organs to HCV-negative recipients, curing and preventing infection with posttransplant DAAs (NEJM JW Infect Dis May 2018 and Ann Intern Med 2018; 168:533). Now, investigators report a single-center study of outcomes in heart and lung recipients.
Forty-four HCV seronegative recipients received organs (36 lung; 8 heart) from HCV-infected donors. Most (42/44) developed detectable posttransplant HCV vir…
Reviewing Author
DisclosuresGrant/Research SupportNobelpharma; Pfizer
Leadership Positions in Professional SocietiesAmerican Society of Transplantation (Program Committee)
DisclosuresGrant/Research SupportNobelpharma; Pfizer
Leadership Positions in Professional SocietiesAmerican Society of Transplantation (Program Committee)